Jan Burger

39PUBLICATIONS
153CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursOtorhinolaryngology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (39)

|Jun 27, 2026
Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia.

|Mar 25, 2026
NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy.

Alexandre Bazinet, Alessandra Ferrajoli, Nitin Jain

|Feb 12, 2026
Ibrutinib with Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: A Phase II Study.

Mahesh Swaminathan, Alessandra Ferrajoli, Philip A Thompson

|Dec 10, 2025
Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.

Courtney D DiNardo, Wei-Ying Jen, Koichi Takahashi

|Jul 30, 2025
Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL.

Jan A Burger, Paul M Barr, Tadeusz Robak

|Feb 25, 2025
Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.

Courtney D DiNardo, Wei-Ying Jen, Koichi Takahashi

Pageof 7

Frequent Collaborators

13 joint publications

William Wierda

8 joint publications

Nitin Jain

8 joint publications

Zeev Estrov

7 joint publications

Philip Thompson